Neurocrine Biosciences Inc Stock Price, News & Analysis

On September 28, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced new data on ONGENTYS^® (opicapone) capsules, the first once-daily COMT inhibitor approved by the FDA for Parkinson's disease patients experiencing 'off' episodes. Phase III analyses reveal ONGENTYS significantly reduces overnight 'off' time and motor fluctuations compared to entacapone. This data will be presented at the American Neurological Association 2020 Virtual Meeting. ONGENTYS also shows promise in lowering daily levodopa requirements, enhancing 'on' time without troublesome dyskinesia.

Neurocrine Biosciences has announced the availability of ONGENTYS (opicapone) in 50 mg capsules, the first FDA-approved once-daily COMT inhibitor for Parkinson's disease. Approved on April 24, 2020, ONGENTYS is an add-on treatment for patients experiencing 'off' episodes while on levodopa/carbidopa. Approximately 1 million Americans suffer from Parkinson's, with about 50,000 new diagnoses each year. Clinical studies indicate ONGENTYS significantly reduces 'off' time and increases 'on' time without troublesome dyskinesia, reflecting a commitment to innovative therapies in movement disorders.

Neurocrine Biosciences (NBIX) announced significant results from post-hoc analyses of Phase III studies demonstrating that ONGENTYS (opicapone) capsules effectively reduce "off" time and increase "on" time in Parkinson's disease patients as an add-on to levodopa/carbidopa. ONGENTYS, approved by the FDA in April 2020, showed that 50 mg doses reduced "off" time by over an hour compared to placebo. Additionally, real-world data revealed increased hospitalization rates linked with prolonged motor fluctuations. The data will be showcased at the MDS Virtual Congress 2020.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET. CEO Kevin Gorman and CFO Matt Abernethy will lead the presentation. The event will be webcast live and can be accessed via the company's website. A replay will be available approximately one hour post-event and archived for one month. Neurocrine, based in San Diego, specializes in treatments for neurological, endocrine, and psychiatric disorders, with multiple FDA-approved products in its portfolio.

Neurocrine Biosciences will present data from 30 abstracts on its movement disorder programs at the 2020 Psych Congress and MDS Virtual Congress. Key highlights include findings from Phase III studies of INGREZZA (valbenazine) for tardive dyskinesia, and ONGENTYS (opicapone) for Parkinson's disease. The data demonstrates sustained clinical benefits and safety for patients. The ongoing commitment to improving patient lives is emphasized by Chief Medical Officer Eiry W. Roberts, M.D. These presentations underline Neurocrine's focus on addressing movement disorders and enhancing treatment outcomes.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference on September 9, 2020, at 12:35 p.m. ET. CEO Kevin Gorman will deliver the presentation, which will be available via a live webcast on the company's website. A replay of the presentation will be accessible approximately one hour after the event, remaining archived for about a month. Neurocrine is focused on developing treatments for neurological and psychiatric disorders, with several FDA-approved products and ongoing clinical programs.

Neurocrine Biosciences (NBIX) reported strong Q2 2020 results, with total revenues of $302.4 million, a 65% increase year-over-year, driven primarily by INGREZZA sales of $267.6 million, up 48%. GAAP net income was $79.6 million, or $0.81 per share, compared to $51.3 million and $0.54 in the prior year. The company revised its full-year expense guidance upward, now estimating combined GAAP R&D and SG&A expenses of $850-$900 million, reflecting increased costs related to licensing agreements. The FDA approval of ONGENTYS is expected to enhance growth prospects further.

On July 30, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the William Blair Biotech Focus Conference 2020, scheduled for August 6, 2020, at 12:00 p.m. ET. Kyle Gano, Chief Business Development and Strategy Officer, will lead a panel on "New Therapies Impacting the Epilepsy Treatment Landscape." The event will be webcasted live, with a replay available on the company's website within an hour post-event. Neurocrine Biosciences specializes in developing treatments for neurological and psychiatric disorders, with a strong portfolio of FDA-approved therapies.

Neurocrine Biosciences (Nasdaq: NBIX) announced it will report its Q2 financial results on August 3, 2020, after market close. A conference call will occur at 1:30 PM PT to discuss the results and provide company updates. Participants can join by dialing 877-876-9173 (US) or 785-424-1667 (International) using conference ID: NBIX. The event will also be available via webcast on Neurocrine's website, with a replay accessible for about one month. The company specializes in treatments for neurological and endocrine disorders, with a diverse portfolio of FDA-approved products.